Eleven Biotherapeutics Inc. (EBIO) Hits New 12-Month High at $5.77
Shares of Eleven Biotherapeutics Inc. (NASDAQ:EBIO) hit a new 52-week high on Monday . The stock traded as high as $5.77 and last traded at $5.50, with a volume of 7,088,197 shares trading hands. The stock had previously closed at $4.71.
The stock’s 50-day moving average price is $2.99 and its 200 day moving average price is $1.36. The stock’s market capitalization is $84.66 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last announced its quarterly earnings data on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) EPS for the current year.
In other Eleven Biotherapeutics news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $2.74, for a total transaction of $2,855,080.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.